Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

(S)-oxybutynin (Sepracor).

Roger R Dmochowski1

  • 1Department of Urology, Vanderbilt University, Nashville, TN 37232, USA. roger.dmochowski@mcmail.vanderbilt.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urobiome Analysis in Interstitial Cystitis/Bladder Pain Syndrome Reveals Nuanced Differences Associated with Localized Pain.

International urogynecology journal·2026
Same author

Treatment of refractory idiopathic overactive bladder with incobotulinumtoxinA and vibe delivery system (XAVIER): pilot study.

Minerva urology and nephrology·2026
Same author

Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective.

Journal of medical economics·2026
Same author

Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study.

The Journal of urology·2026
Same author

Impact of Revi® Implantable Tibial Neuromodulation on Quality of Life in Patients with Urgency Urinary Incontinence.

International urogynecology journal·2026
Same author

Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder.

Journal of comparative effectiveness research·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Sepracor is developing (S)-oxybutynin, a single-isomer drug, to treat urinary incontinence. This new form of oxybutynin aims to improve upon the existing racemic version.

Area of Science:

  • Pharmacology
  • Urology
  • Drug Development

Background:

  • Urinary incontinence is a common condition affecting many individuals.
  • Current treatments include medications like racemic oxybutynin.
  • Racemic oxybutynin, while effective, may have limitations or side effects.

Purpose of the Study:

  • To develop a single-isomer version of oxybutynin, known as (S)-oxybutynin.
  • To evaluate (S)-oxybutynin as a potential treatment for urinary incontinence.
  • To explore potential improvements over the existing racemic oxybutynin formulation.

Main Methods:

  • Development of a single-isomer formulation of oxybutynin.
  • Preclinical and/or clinical studies to assess efficacy and safety.
  • Characterization of (S)-oxybutynin as a muscarinic acetylcholine receptor antagonist.

Related Experiment Videos

Main Results:

  • Successful development of (S)-oxybutynin.
  • Demonstration of (S)-oxybutynin's activity as a muscarinic antagonist.
  • Potential for improved therapeutic profile compared to racemic oxybutynin (further studies needed).

Conclusions:

  • Single-isomer (S)-oxybutynin is a promising candidate for treating urinary incontinence.
  • This development represents an advancement in the pharmacological treatment of bladder control disorders.
  • (S)-oxybutynin may offer a more targeted or effective therapeutic option.